Tydemy — Class III drug recall D-0264-2022
Terminated recall by Lupin Pharmaceuticals Inc., reported 2021-12-08, distributed nationwide. Subpotent Drug
| Recall number | D-0264-2022 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Lupin Pharmaceuticals Inc., Baltimore, MD, United States |
| Recall initiated | 2021-11-19 |
| Classified | 2021-12-01 |
| Reported by FDA | 2021-12-08 |
| Terminated | 2022-11-15 |
| Distributed | Nationwide (US) |
| Quantity | 4,113 cartons |
| Reason classes | potency |
| NDC | 68180-0904-11, 68180-0904-13 |
| Lot numbers | L000784, L000785 |
| Expiration dates | 2022-05-20 |
Product
Tydemy (drospirenone, ethinyl estradiol & levomefolate calcium tablets, 3 mg/0.03 mg/0.451 mg and levomefolate calcium tablets, 0.451 mg), packaged in cartons containing 3 wallets of 28 Tablets each, Rx Only, Distributed by: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202, United Stated, Manufactured by: Lupin Limited, Pithampur, (M.P.) - 454775, India, 244896, The individual wallet NDC 68180-904-11 and the carton NDC 68180-904-13.
Reason for recall
Subpotent Drug
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0264-2022. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.